Published on 28/12/2025
Managing Adhesion Failures in Enteric-Coated Tablet Layers During Validation Runs
Introduction:
Enteric-coated tablets are a vital component of modern pharmaceutical formulations, designed to protect active ingredients from the acidic environment of the stomach and ensure targeted release in the intestines. However, ensuring the effective adhesion of enteric coatings is crucial, especially during validation runs, where adhesion failures can lead to compromised drug efficacy and patient safety. This blog post delves into the intricacies of managing adhesion failures in enteric-coated tablet layers, providing a comprehensive guide for pharmaceutical professionals.
Challenges and Issues:
- Inadequate Coating Adhesion: Poor adhesion can result from improper formulation or process parameters leading to coating peeling or flaking.
- Moisture Sensitivity: High humidity levels during the coating process can adversely affect the adhesion of the enteric layer.
- Inconsistent Coating Thickness: Variability in coating thickness may lead to non-uniform drug release profiles.
- Substrate Compatibility: Incompatible core tablet properties can hinder effective bonding of the coating layer.
- Environmental Conditions: External factors such as temperature and humidity during storage and processing can influence adhesion quality.
Step-by-Step Troubleshooting Guide:
- Identify the Root Cause: Conduct a thorough analysis of the formulation and process parameters. Utilize tools like root cause analysis (RCA) and failure
Regulatory Guidelines:
Adhering to regulatory guidelines is crucial in pharmaceutical manufacturing. The USFDA provides comprehensive guidelines on tablet coating processes and validation requirements. Ensuring compliance with these standards not only ensures product quality but also facilitates regulatory approval. Additionally, guidelines from other regulatory bodies such as the European Medicines Agency (EMA) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) should also be considered.
Conclusion:
Managing adhesion failures in enteric-coated tablet layers is an intricate task that requires a thorough understanding of both formulation and process parameters. By identifying the root causes, optimizing formulations, and controlling environmental conditions, pharmaceutical professionals can effectively address adhesion issues. Adhering to regulatory guidelines ensures that the quality and efficacy of the final product are maintained. Through diligent troubleshooting and adherence to best practices, the challenges associated with enteric coating adhesion can be effectively managed, ensuring the production of high-quality pharmaceutical products.